JP2023503061A5 - - Google Patents

Info

Publication number
JP2023503061A5
JP2023503061A5 JP2022529041A JP2022529041A JP2023503061A5 JP 2023503061 A5 JP2023503061 A5 JP 2023503061A5 JP 2022529041 A JP2022529041 A JP 2022529041A JP 2022529041 A JP2022529041 A JP 2022529041A JP 2023503061 A5 JP2023503061 A5 JP 2023503061A5
Authority
JP
Japan
Prior art keywords
cells
car
pharmaceutical composition
akt inhibitor
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022529041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503061A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/061107 external-priority patent/WO2021102038A1/en
Publication of JP2023503061A publication Critical patent/JP2023503061A/ja
Publication of JP2023503061A5 publication Critical patent/JP2023503061A5/ja
Pending legal-status Critical Current

Links

JP2022529041A 2019-11-18 2020-11-18 キメラｔ細胞の持続性を強化するためのａｋｔ阻害剤 Pending JP2023503061A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962937028P 2019-11-18 2019-11-18
US62/937,028 2019-11-18
US201962937359P 2019-11-19 2019-11-19
US62/937,359 2019-11-19
US201962942662P 2019-12-02 2019-12-02
US62/942,662 2019-12-02
US201962944295P 2019-12-05 2019-12-05
US62/944,295 2019-12-05
US202062982480P 2020-02-27 2020-02-27
US62/982,480 2020-02-27
PCT/US2020/061107 WO2021102038A1 (en) 2019-11-18 2020-11-18 Akt inhibitors for enhancing chimeric t cell persistence

Publications (2)

Publication Number Publication Date
JP2023503061A JP2023503061A (ja) 2023-01-26
JP2023503061A5 true JP2023503061A5 (https=) 2023-11-28

Family

ID=75981019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022529041A Pending JP2023503061A (ja) 2019-11-18 2020-11-18 キメラｔ細胞の持続性を強化するためのａｋｔ阻害剤

Country Status (11)

Country Link
US (1) US20230039099A1 (https=)
EP (1) EP4061383A4 (https=)
JP (1) JP2023503061A (https=)
KR (1) KR20220130100A (https=)
CN (1) CN115175686A (https=)
AU (1) AU2020387407A1 (https=)
BR (1) BR112022009607A2 (https=)
CA (1) CA3162094A1 (https=)
IL (1) IL293094A (https=)
MX (1) MX2022005973A (https=)
WO (1) WO2021102038A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116390734A (zh) * 2020-09-25 2023-07-04 中国科学院动物研究所 增强t细胞功能的化合物和方法
EP4340852A4 (en) * 2021-05-19 2025-05-07 Prescient Therapeutics Ltd METHODS FOR PRODUCING ENHANCED IMMUNE CELL POPULATIONS
CN113943710B (zh) * 2021-09-17 2023-03-24 浙江大学医学院附属第一医院 一种car-t细胞培养用的培养基及其应用
CN118956769B (zh) * 2024-10-15 2025-01-14 深圳泰华赛尔生物科技有限公司 一种提高car-t细胞功能的培养基及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005024042A2 (en) * 2003-09-04 2005-03-17 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
RU2018105118A (ru) * 2015-08-21 2019-09-23 Пфайзер Инк. Терапевтические наночастицы, содержащие терапевтический агент, и способы их получения и применения
KR20180063320A (ko) * 2015-10-20 2018-06-11 카이트 파마 인코포레이티드 T 세포 요법을 위한 t 세포를 제조하는 방법
US11479755B2 (en) * 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
CN121102467A (zh) * 2016-04-22 2025-12-12 克莱格医学有限公司 用于细胞免疫疗法的组合物和方法

Similar Documents

Publication Publication Date Title
JP2023503061A5 (https=)
Shimasaki et al. Expanded and armed natural killer cells for cancer treatment
Tey et al. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation
Dickinson et al. Graft-versus-leukemia effect following hematopoietic stem cell transplantation for leukemia
Micklethwaite et al. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation
AU2025252604A1 (en) Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
US20250283040A1 (en) Methods to Expand a T Regulatory Cell Master Cell Bank
Shook et al. Natural killer cell engineering for cellular therapy of cancer
JP2016520074A5 (https=)
Kaweme et al. Optimizing NK cell-based immunotherapy in myeloid leukemia: abrogating an immunosuppressive microenvironment
Hasan et al. Artificial antigen presenting cells: an off the shelf approach for generation of desirable T-cell populations for broad application of adoptive immunotherapy
JP2019530449A (ja) 幹細胞様メモリーｔ細胞の生成および養子免疫療法における使用
Cruz et al. T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect
JP2022532996A5 (https=)
Song et al. Cooperation between CD4 and CD8 T cells for anti‐tumor activity is enhanced by OX40 signals
JP2021536260A5 (https=)
Tal et al. An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities
CN115698038A (zh) 信号转换受体及其用途
JP2023525020A5 (https=)
Van Caeneghem et al. Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities
JP2024525609A5 (https=)
CN120641113A (zh) 靶向cd20和bcma的双特异性嵌合抗原受体
US20220056411A1 (en) Methods for isolating cd8+ selected t cells
US20250144211A1 (en) Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding
Hildebrandt et al. Immunotherapy: opportunities, risks and future perspectives